According to Stirling Products, the company is in discussions with several major pharmaceutical companies about partnerships on products using its patented high density aerosol (HDA) device. The company says that its ultrasound-based HDA technology produces a concentration level three times higher than that of other ultrasonic devices. One version of the device has 510(k) approval, and Stirling says that it is developing more advanced versions. Read the company’s press release.
Stirling talking to potential partners for HDA device
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
